Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00214
UPID:
LEG8_HUMAN
Alternative names:
Po66 carbohydrate-binding protein; Prostate carcinoma tumor antigen 1
Alternative UPACC:
O00214; O15215; Q5T3P5; Q5T3Q4; Q8TEV1; Q96B92; Q9BXC8; Q9H584; Q9H585; Q9UEZ6; Q9UP32; Q9UP33; Q9UP34
Background:
Galectin-8, identified by its alternative names Po66 carbohydrate-binding protein and Prostate carcinoma tumor antigen 1, is a beta-galactoside-binding lectin. It plays a crucial role in sensing membrane damage caused by infection, thereby restricting the proliferation of pathogens by targeting them for autophagy. Galectin-8 detects membrane rupture by binding to beta-galactoside ligands exposed to the cytoplasm following rupture. It is pivotal in initiating autophagy via interaction with CALCOCO2/NDP52, essential for combating bacterial invasions like S.typhimurium and Picornaviridae viruses. Galectin-8 shows a marked preference for 3'-O-sialylated and 3'-O-sulfated glycans.
Therapeutic significance:
Understanding the role of Galectin-8 could open doors to potential therapeutic strategies.